Beam Therapeutics Inc Earnings
The next earnings date for Beam Therapeutics Inc has not yet been scheduled.
Analyst Estimates of Beam Therapeutics Inc Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Beam Therapeutics Inc Earnings: Historical
| 11/03/2026 | Before Market | $-1.28 | -9.40% |
| 08/04/2026 | Before Market | $-1.18 | -218.00% |
| 05/07/2026 | Before Market | $-0.91 | 9.90% |
| 02/24/2026 | --- | $2.33 | 330.69% |
| 11/04/2025 | Before Market | $-1.10 | -8.91% |
| 08/05/2025 | Before Market | $-1 | 8.26% |
| 05/06/2025 | Before Market | $-1.24 | -5.98% |
| 02/25/2025 | Before Market | $-1.09 | 10.35% |
| 11/05/2024 | Before Market | $-1.17 | 0.85% |
| 08/06/2024 | Before Market | $-1.11 | 0.89% |
More About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
“Beam Therapeutics Inc Earnings” Can Refer to the Beam Therapeutics Inc Earnings Date
Some people say “Beam Therapeutics Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Beam Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Beam Therapeutics Inc Stock on the Earnings Date
If you own Beam Therapeutics Inc stock (BEAM) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Beam Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Beam Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Beam Therapeutics Inc Earnings
You can contact us any time if you would like to ask questions about Beam Therapeutics Inc earnings or anything else related to the stock market.